128 related articles for article (PubMed ID: 16796723)
1. Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children.
Comoli P; Ginevri F; Maccario R; Frasson C; Valente U; Basso S; Labirio M; Huang GC; Verrina E; Baldanti F; Perfumo F; Locatelli F
Am J Transplant; 2006 Sep; 6(9):2169-76. PubMed ID: 16796723
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals.
Metes D; Storkus W; Zeevi A; Patterson K; Logar A; Rowe D; Nalesnik MA; Fung JJ; Rao AS
Transplantation; 2000 Nov; 70(10):1507-15. PubMed ID: 11118098
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo priming of naïve T cells into EBV-specific Th1/Tc1 effector cells by mature autologous DC loaded with apoptotic/necrotic LCL.
Popescu I; Macedo C; Zeevi A; Nellis J; Patterson KR; Logar A; Rowe D; Reyes J; Rao AS; Storkus WJ; Fung JJ; Metes D
Am J Transplant; 2003 Nov; 3(11):1369-77. PubMed ID: 14525597
[TBL] [Abstract][Full Text] [Related]
4. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals.
Savoldo B; Cubbage ML; Durett AG; Goss J; Huls MH; Liu Z; Teresita L; Gee AP; Ling PD; Brenner MK; Heslop HE; Rooney CM
J Immunol; 2002 Jan; 168(2):909-18. PubMed ID: 11777989
[TBL] [Abstract][Full Text] [Related]
5. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
[TBL] [Abstract][Full Text] [Related]
6. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
[TBL] [Abstract][Full Text] [Related]
7. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
Nowakowska J; Stuehler C; Egli A; Battegay M; Rauser G; Bantug GR; Brander C; Hess C; Khanna N
Cytotherapy; 2015 Sep; 17(9):1280-91. PubMed ID: 26276009
[TBL] [Abstract][Full Text] [Related]
8. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
9. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
[TBL] [Abstract][Full Text] [Related]
10. Relationship between CD8+ T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study.
Baudouin V; Dehée A; Pédron-Grossetete B; Ansart-Pirenne H; Haddad E; Maisin A; Loirat C; Sterkers G
Transplantation; 2004 Jun; 77(11):1706-13. PubMed ID: 15201670
[TBL] [Abstract][Full Text] [Related]
11. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
Ning RJ; Xu XQ; Chan KH; Chiang AK
Immunology; 2011 Oct; 134(2):161-71. PubMed ID: 21896011
[TBL] [Abstract][Full Text] [Related]
12. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
14. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
Khanolkar A; Fu Z; Underwood LJ; Bondurant KL; Rochford R; Cannon MJ
J Immunol; 2003 Mar; 170(6):3187-94. PubMed ID: 12626577
[TBL] [Abstract][Full Text] [Related]
15. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
[TBL] [Abstract][Full Text] [Related]
16. EBV-specific CD8+ T cell reactivation in transplant patients results in expansion of CD8+ type-1 regulatory T cells.
Popescu I; Macedo C; Abu-Elmagd K; Shapiro R; Hua Y; Thomson AW; Morelli AE; Storkus WJ; Metes D
Am J Transplant; 2007 May; 7(5):1215-23. PubMed ID: 17331111
[TBL] [Abstract][Full Text] [Related]
17. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
Ramadan G
Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
[TBL] [Abstract][Full Text] [Related]
19. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis.
Pender MP; Csurhes PA; Lenarczyk A; Pfluger CM; Burrows SR
J Neurol Neurosurg Psychiatry; 2009 May; 80(5):498-505. PubMed ID: 19015225
[TBL] [Abstract][Full Text] [Related]
20. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens.
Yang J; Lemas VM; Flinn IW; Krone C; Ambinder RF
Blood; 2000 Jan; 95(1):241-8. PubMed ID: 10607708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]